Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Aug 04, 2021 11:04am
141 Views
Post# 33648124

Oncology and NASH

Oncology and NASHSince the ER they have posted three times articles and quizzes related to growing prevalence of NASH, the latest was posted today. So they want to educate their followers re the market opportunities for an approved drug for a growing condition.
 
https://www.linkedin.com/posts/theratechnologies-inc_nash-activity-6828640816806920192-hBPV
 
They have a clinical project manager based in Dublin, I am not sure when she joined the company or whether she was involved with the approval of Trogarzo in Europe but why keeping her on their payroll if they are not planning clinical trials in Europe which brings me to again the speculative thoughts about an IND for oncology in Europe.
Below is what she is supposed to do and her skills…
 
 
https://www.linkedin.com/in/rebecca-lee-/?originalSubdomain=ie
“About
Agile and highly motivated Clinical Project Manager with over 15 years’ experience in clinical research and development. Experienced in delivering clinical trials on time, within budget and to the highest possible quality standards to fulfil the requirements of the drug development plan. Outgoing, passionate and adept at working across therapy areas and management levels with a proven track record in leadership and delivery developed through a career in the pharmaceutical and CRO industries.
 
Key Skills
• Project Management and Delivery
• Budgeting and Resource Forecasting
• Risk Management & Mitigation
• Stakeholder and Team Management
• In Depth Knowledge of Good Clinical Practice and applicable regulations
• Inspection Readiness
• Vendor Management
• Mentoring & Coaching
• Training
• Drug Discovery
• Drug Development
• Trial Master File Management
• Electronic Data Capture Systems –Inform, Rave, RDC”
 
Just to get an idea of the cancers’ market I found this article which is stating the economic burden of colorectal cancer across Europe in 2015 was €19·1 billion, now this is obviously for all stages of that cancer but if and when their PDC gets approved possibly for more cancers the market opportunities both in the US and Europe are putting it mildly great.
 
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00147-3/fulltext
 
Another study published recently highlighting the growing prevalence of cancers:
 
“The burden of cancer and the projected increase in cancer incidence, estimated to be 25% by 2035, is a global policy concern. 1 If no further action is taken, cancer will soon be the number one cause of death in high-income countries. Therefore, it is encouraging to have comprehensive data of the economic effect of colorectal cancer across Europe, as reported by Raymond Henderson and colleagues in the Lancet Gastroenterology & Hepatology.”
 
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00177-1/fulltext

<< Previous
Bullboard Posts
Next >>